<DOC>
	<DOCNO>NCT02121860</DOCNO>
	<brief_summary>This open-label , parallel-group study compare pharmacokinetics pharmacodynamics IDN-6556 follow single 50 mg oral dose IDN-6556 subject mild , moderate , severe hepatic impairment ( define Child-Pugh A , B , C , respectively ) match healthy volunteer normal hepatic function .</brief_summary>
	<brief_title>PK PD Study IDN-6556 Subjects With Hepatic Impairment Matched Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<criteria>All Subjects : Male female subject 18 year age old , able provide write informed consent , understand comply schedule visit , requirement study Body mass index ( BMI ) 18.0 40.0 kg/m2 body weight &gt; 45 kg Willingness utilize two reliable form contraception ( male females childbearing potential ) Screening one month last dose study drug Matched Healthy Volunteers : Medically healthy determine Investigator Supine blood pressure ≤145/90 mmHg No significant uncontrolled systemic major illness , opinion Investigator , would preclude subject participate complete study Demographically comparable subject hepatic impairment follow : 1 . Mean body weight within ±15 kg 2 . Mean age within ±10 year 3 . Similar gender ratio Subjects Hepatic Impairment : Evidence hepatic disease 1 . Score ≥ 2 one ChildPugh parameter , 2 . Histological image diagnosis cirrhosis , 3 . Presence esophageal varix , 4 . Abnormal alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase ( ALP ) level Meet one follow criterion ChildPugh classification hepatic impairment Screening 1 . Mild hepatic impairment : Class A ( ChildPugh Scores 56 point ) 2 . Moderate hepatic impairment : Class B ( ChildPugh Scores 79 point ) 3 . Severe hepatic impairment : Class C ( Child Pugh Scores 1015 point ) Supine blood pressure ≤160/100 mmHg All Subjects : Known infection human immunodeficiency virus ( HIV ) upon serological test Evidence clinically significant uncontrolled hematological , endocrine , pulmonary , gastrointestinal , cardiovascular , renal , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) Disorders surgery gastrointestinal tract may interfere drug absorption may otherwise influence pharmacokinetics investigational medicinal product ( e.g. , inflammatory bowel disease , resection small large intestine , etc . ) History febrile illness within 5 day prior dose Note : Subjects rescreened afebrile 5 day elapse since febrile illness . Known ongoing drug abuse within one month prior dose , evidence abuse indicate laboratory assay conduct Screening and/or Day 1 Subjects active history malignancy curatively treat skin cancer ( basal cell squamous cell carcinoma ) Dosing another clinical trial within 30 day prior study drug administration If female : know pregnancy , positive urine serum pregnancy test , lactating/breastfeeding Matched Healthy Volunteers : Evidence clinically significant liver disease liver damage ( e.g. , hepatitis B C , autoimmune hepatitis , primary biliary cirrhosis , nonalcoholic fatty liver disease , elevate aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) consider clinically significant Investigator , etc . ) Screening creatinine clearance &lt; 80 mL/min use CockcroftGault equation History presence clinically concern cardiac arrhythmia , prolongation Screening ( pretreatment ) QT QTc interval &gt; 450 millisecond ( msec ) History regular alcohol consumption exceed 28 drinks/week ( 1 drink = 150 mL wine 360 mL beer 45 mL spirit ) within 6 month Screening Subjects Hepatic Impairment : Fluctuating rapidly deteriorate hepatic function , indicate strongly vary worsen clinical and/or laboratory sign hepatic impairment Screening period Day 1 ( e.g. , advanced ascites , infection ascites , fever , active gastrointestinal bleeding ) History liver transplant , transjugular intrahepatic portosystemic shunt , and/or undergone portacaval shunt History presence clinically concern cardiac arrhythmia , prolongation Screening ( pretreatment ) QT QTc interval &gt; 480 millisecond ( msec ) Screening creatinine clearance &lt; 50 mL/min use CockcroftGault equation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Hepatic Impairment</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>